Surrozen Crescita futura

Future criteri di controllo 0/6

Si prevede che i ricavi e gli utili di Surrozen diminuiranno rispettivamente del 78.8% e 12.2% all'anno, mentre si prevede che l'EPS crescerà del 56.1% all'anno.

Informazioni chiave

-12.2%

Tasso di crescita degli utili

56.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	-78.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	07 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Aug 21

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:SRZN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-53	N/A	-37	2
12/31/2025	N/A	-42	N/A	-32	2
12/31/2024	10	-44	N/A	-29	1
9/30/2024	10	-44	-28	-28	N/A
6/30/2024	N/A	-53	-32	-32	N/A
3/31/2024	N/A	-38	-35	-35	N/A
12/31/2023	N/A	-43	-41	-40	N/A
9/30/2023	13	-35	-34	-33	N/A
6/30/2023	13	-38	-38	-37	N/A
3/31/2023	13	-42	-41	-40	N/A
12/31/2022	13	-36	-45	-44	N/A
9/30/2022	N/A	-50	-56	-55	N/A
6/30/2022	N/A	-51	-57	-55	N/A
3/31/2022	N/A	-50	-58	-57	N/A
12/31/2021	N/A	-55	-50	-49	N/A
9/30/2021	N/A	-51	-48	-47	N/A
6/30/2021	N/A	-45	-41	-40	N/A
3/31/2021	N/A	-39	-35	-33	N/A
12/31/2020	N/A	-33	-30	-29	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che SRZN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che SRZN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che SRZN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di SRZN diminuiranno nei prossimi 3 anni ( -78.8% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di SRZN diminuiranno nei prossimi 3 anni ( -78.8% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SRZN è previsto essere elevato tra 3 anni

Surrozen Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 45% to US$33.00

Price target decreased to US$12.50

Price target increased to US$19.50

Recent updates

New major risk - Financial position

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Price target decreased by 45% to US$33.00

Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita